Tag: PAD

Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization

XARELTO® has the potential to be the first anticoagulant in 20 years(i) to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease RARITAN, N.J., March 28, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […]

Modern Vascular Brings New Treatment Options for Peripheral Artery Disease (PAD) to Denver Residents with the Opening of Its Newest Facility

THORNTON, Colo., March 02, 2020 (GLOBE NEWSWIRE) — Modern Vascular today announced the growth of its national footprint with the opening of a new facility in Thornton, CO, bringing its treatment of Peripheral Artery Disease (PAD) to Denver area residents.  The facility is now open for business and scheduling outpatient […]

JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development

JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, Feb. 6, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs […]

JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week

Dr. Christopher Kevil, pioneer in nitrite based PAD treatment and Dr. Amol Soin, foremost expert is neuropathic pain, provide scientific insight on the pain relieving qualities of JanOne’s lead drug candidate Interview to be distributed nationally on all 193 Sinclair broadcasting network affiliate stations in 89 markets across the nation […]

Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board

Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]

Alucent Biomedical Announces FDA Approval to Proceed with Natural Vascular Scaffolding Clinical Trial

SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. has received U.S. Food and Drug Administration approval to proceed with a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral artery disease (PAD) of the lower extremities, a […]

JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD)

Phase 2b testing planned for PAD treatment and PAD-associated pain to address 8.5 million patient US market LAS VEGAS, Nov. 25, 2019 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on reducing opioid addiction by finding treatments for conditions accompanied by pain and bringing to market drugs and therapies with nonaddictive pain-relieving properties, […]

LimFlow Announces Positive Six-Month Data From Promise I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-Option Patient Population

Results Presented Today at Vascular Interventional Advances (VIVA) Conference PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the presentation of positive six-month data from the full patient cohort in […]

THE SAGE GROUP LLC Comments on National Peripheral Artery Disease (PAD) Awareness Month

BEAUFORT, S.C.–(BUSINESS WIRE)–According to THE SAGE GROUP, in 2015 almost 20 million Americans suffered from PAD representing an economic burden of $224-$414 billion. “Almost 20 years ago, we wrote that PAD was underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President. “Unfortunately, this is still true.” Reflecting on the current […]